Aquesta Specialised Uropathology, Brisbane, Qld, Australia; Rennes University Hospital, Rennes, France; University of Rennes, Rennes, France.
Aquesta Specialised Uropathology, Brisbane, Qld, Australia; Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington, New Zealand.
Pathology. 2019 Jun;51(4):349-352. doi: 10.1016/j.pathol.2019.01.004. Epub 2019 Apr 12.
Heterogeneity of tumour grading is common in clear cell renal cell carcinoma (ccRCC). WHO/ISUP grading specifies that RCC should be graded based on the highest grade present in at least one high power field. This does not take into account the proportion of high grade tumour present in a cancer, which may itself influence outcome. Cases of ccRCC accessioned by Aquesta Uropathology, Brisbane, Australia, between 2008 and 2015, were reviewed and grading assigned according to WHO/ISUP criteria. For tumours classified as grade 3 (G3) and 4 (G4), the percentage of tumour showing G3 and G4 morphology was assessed for each case. Survival analysis, with time to the development of metastases as the clinical outcome, was performed for six grading subclasses (G3 <10%, G3 10-50%, G3 >50%, G4 <10%, G4 10-50%, G4 >50%). Of the 681 cases of ccRCC in the series, there were 153 cases classified as G3 (91 cases) and G4 (62 cases) for which follow-up was available. During the follow-up period of <1-89 months, 19 (20.9%) patients with G3 and 30 (48.3%) patients with G4 cancers developed metastatic disease. The three subgroups of <10%, 10-50% and >50% G3 tumour were not significant in predicting outcome (p=0.47). Separating G3 into two groups of ≤50% vs >50% was also not significantly associated with outcome (p=0.22). For the three subgroups of G4 ccRCC (<10%, 10-50% and >50% G4) a higher percentage of G4 correlated with time to the development of metastases (p=0.01). Even though G4 tumours as a whole had a significantly worse outcome than G3 tumours (p=0.0004), the difference between G4 <10% and G3 tumours was not significant (p=0.27). On multivariate analysis, that included pT staging category and tumour size, there was a significant difference in survival between G4<10% and G4>50% tumours (p=0.018). The results of the study suggest that for ccRCC, WHO/ISUP G4 category should incorporate the percentage of G4 tumour present.
肿瘤分级的异质性在透明细胞肾细胞癌(ccRCC)中很常见。世界卫生组织/国际泌尿系统病理学会(WHO/ISUP)分级规定,RCC 的分级应基于至少一个高倍视野中存在的最高级别。但该分级标准未考虑肿瘤中高级别肿瘤的比例,而肿瘤中高级别肿瘤的比例可能本身会影响预后。本研究回顾了 2008 年至 2015 年期间澳大利亚布里斯班的 Aquesta 泌尿病理学收集的 ccRCC 病例,并根据 WHO/ISUP 标准进行分级。对于分级为 3 级(G3)和 4 级(G4)的病例,评估了每个病例中显示 G3 和 G4 形态的肿瘤百分比。以转移发生时间为临床结局,对 6 个分级亚组(G3<10%、G3 10-50%、G3>50%、G4<10%、G4 10-50%、G4>50%)进行生存分析。在该系列中 681 例 ccRCC 病例中,有 153 例 G3(91 例)和 G4(62 例)病例有随访资料。在随访时间<1-89 个月期间,19 例(20.9%)G3 癌症患者和 30 例(48.3%)G4 癌症患者发生了转移性疾病。G3 肿瘤<10%、10-50%和>50%的三个亚组在预测结局方面无显著差异(p=0.47)。将 G3 分为≤50%和>50%两组也与结局无显著相关性(p=0.22)。对于 G4 ccRCC 的三个亚组(<10%、10-50%和>50%G4),G4 比例越高,发生转移的时间越短(p=0.01)。尽管 G4 肿瘤的整体预后明显差于 G3 肿瘤(p=0.0004),但 G4<10%与 G3 肿瘤之间的差异无统计学意义(p=0.27)。多因素分析包括 pT 分期和肿瘤大小,G4<10%和 G4>50%肿瘤之间的生存差异有统计学意义(p=0.018)。该研究结果表明,对于 ccRCC,WHO/ISUP G4 类别应纳入存在的 G4 肿瘤比例。